SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurogen (NRGN)
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
523 35 0 NRGN
Emcee:  Terry McCormick Type:  Unmoderated
Introduction Market Data Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
23 FYI; there was a 300,000 share trade today and apparently three, 100,000 tradesphbolton-12/20/1996
22 Neurogen, Synaptic -2: B. Stearns Starts Coverage >NRGN SNAP NEW YORK (Dow phbolton-12/14/1996
21 91-1 is the drug candidate that has been dropped by Pfizer from development duescaram(o)uche-12/12/1996
20 Richard: You make some good insider points, but what are you referring to as &M. Brett Burns-12/11/1996
19 Mohan...... the hurt on 91-1 justifies the drop, IMO. However, if you love hiscaram(o)uche-12/11/1996
18 Well, as soon as I saw the drop and the news I put in a big bid at 18 and unforphbolton-12/11/1996
17 Richard, NRGN is down over 3 points today. The only news I saw is this. Does itCynic 2005-12/11/1996
16 excerpted from a dec. 4 posting by mike burke on the ask mb thread: . . . Volcano888-12/5/1996
15 Technical advantages: Those that NRGN has are rooted in their approach to rapiTerry McCormick-12/2/1996
14 Re: Easy Money... TANST ;-). I'm no expert at evaluating biotechs, but NRHB-11/27/1996
13 Also, today's issue of Science has an article and a commentary on the "phbolton-11/26/1996
12 Easy money........ Neurogen and Wyeth-Ayerst Announce Licensing Agreement for scaram(o)uche-11/26/1996
11 (thanks, Jim) 11/21 New Obesity Drugs Will Target Fat's Biochemical Causes scaram(o)uche-11/22/1996
10 IMHO leptin may well have the delivery and cost problems commonly associated wiphbolton-11/19/1996
9 Thompson's Market Edge reports no major insider transactions as of Nov. 16.Paul Kern-11/19/1996
8 Nice story on NRGN's psychaitric drugs in the science section of today'Paul Kern-11/19/1996
7 Some good insights on the obesity field can be derived from the following; my iTerry McCormick-11/19/1996
6 thanks, terry and phb, for the prompt replies. i've seen plenty of the ubiqVolcano888-11/19/1996
5 Still here and in holding. This is a long term prospect but with good managemeTerry McCormick-11/18/1996
4 Mike Burke over on his own channel mentions this one occasionally. This is a gphbolton-11/18/1996
3 you still out there? still in nrgn? it's surprising this never generated anVolcano888-11/18/1996
2 More background Neurogen Corporation, based in Branford, CT, develops novel phTerry McCormick-6/25/1996
1 Also: contracted agreements to date: Allaince partner Schering-PloughTerry McCormick-6/25/1996
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News